Gametocyte Clearance in Uncomplicated and Severe Plasmodium falciparum Malaria after Artesunate-Mefloquine Treatment in Thailand.
- Author:
Noppadon TANGPUKDEE
1
;
Srivicha KRUDSOOD
;
Siripan SRIVILAIRIT
;
Nanthaporn PHOPHAK
;
Putza CHONSAWAT
;
Wimon YANPANICH
;
Shigeyuki KANO
;
Polrat WILAIRATANA
Author Information
- Publication Type:Original Article ; Clinical Trial ; Research Support, Non-U.S. Gov't
- Keywords: Plasmodium falciparum; gametocyte clearance time; uncomplicated malaria; severe malaria; artemisinin-based combination therapy; Thailand
- MeSH: Adolescent; Adult; Animals; Antimalarials/*pharmacology/therapeutic use; Artemisinins/*pharmacology/therapeutic use; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Germ Cells/*drug effects/growth & development; Humans; Malaria, Falciparum/*drug therapy/parasitology; Male; Mefloquine/*pharmacology/therapeutic use; Plasmodium falciparum/*drug effects/growth & development; Severity of Illness Index; Thailand; Treatment Outcome
- From:The Korean Journal of Parasitology 2008;46(2):65-70
- CountryRepublic of Korea
- Language:English
- Abstract: Artemisinin-based combination therapy (ACT) is currently promoted as a strategy for treating both uncomplicated and severe falciparum malaria, targeting asexual blood-stage Plasmodium falciparum parasites. However, the effect of ACT on sexual-stage parasites remains controversial. To determine the clearance of sexual-stage P. falciparum parasites from 342 uncomplicated, and 217 severe, adult malaria cases, we reviewed and followed peripheral blood sexualstage parasites for 4 wk after starting ACT. All patients presented with both asexual and sexual stage parasites on admission, and were treated with artesunate-mefloquine as the standard regimen. The results showed that all patients were asymptomatic and negative for asexual forms before discharge from hospital. The percentages of uncomplicated malaria patients positive for gametocytes on days 3, 7, 14, 21, and 28 were 41.5, 13.1, 3.8, 2.0, and 2.0%, while the percentages of gametocyte positive severe malaria patients on days 3, 7, 14, 21, and 28 were 33.6, 8.2, 2.7, 0.9, and 0.9%, respectively. Although all patients were negative for asexual parasites by day 7 after completion of the artesunate-mefloquine course, gametocytemia persisted in some patients. Thus, a gametocytocidal drug, e.g., primaquine, may be useful in combination with an artesunate-mefloquine regimen to clear gametocytes, so blocking transmission more effectively than artesunate alone, in malaria transmission areas.
